Novel Target for the Treatment of GlaucomaTechnology #ua11-125
Questions about this technology? Ask a Technology Manager
Title: Control of Intraocular Pressure by Modification of Soluable Adenylate Cyclase Activity
Invention: The technology is the manipulation of anterior chamber drainage in the eye by targeting unique pathways. Bicarbonate sensitive soluble adenylyl cyclase regulates the secretion of substances into the aqueous humor and resulting pressure. Deficiency in bicarbonate channel bestrophin-2 was shown to have a lower intraocular pressure.
Background: Glaucoma is the leading cause of blindness, affecting 2.2 million individuals in the United States. Current glaucoma treatment involves reducing intraocular pressure and reducing the resistance to drainage of aqueous humor. Carbonic anhydrase inhibitors, one of the drugs used to treat glaucoma, has a poorly understood role in regulating aqueous flow. Researchers at the University of Arizona have discovered a potential new pathway to reduce intraocular pressure via bestrophins. In the eye, bestrophins, which function as anion channels and regulators of calcium signaling, are located in non-pigmented ciliary epithelial cells.
- Glaucoma treatment
- Potential screening as a biomarker
- A newly targeted pathway for glaucoma treatments